Research graph
References from Oral selective estrogen receptor degraders in ER+/HER2− breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21660 · 2021 · External reference
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
10.1016/s0140-6736(15)61074-1 · 2015 · External reference
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
10.1056/nejmoa1701830 · 2017 · External reference
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
10.1126/scitranslmed.aac7551 · 2015 · External reference
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
10.1016/j.pharmthera.2017.12.012 · 2018 · External reference
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized Phase III EMERALD trial
10.1200/jco.22.00338 · 2022 · External reference
Imlunestrant with or without abemaciclib in advanced breast cancer
10.1056/nejmoa2410858 · 2025 · External reference
Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2- advanced breast cancer: an updated systematic review and meta-analysis of randomized controlled trials
10.1016/j.ctrv.2026.103093 · 2026 · External reference
Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis
10.1007/s10549-026-07962-0 · 2026 · External reference
Giredestrant versus standard-of-care endocrine therapy as adjuvant treatment for ER-positive, HER2-negative early breast cancer: results from the global phase III lidERA Breast Cancer trial
2025 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.31222/osf.io/v7gm2 · 2021 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
Measuring inconsistency in meta-analyses
10.1136/bmj.327.7414.557 · 2003 · External reference
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
10.1016/s1470-2045(24)00387-5 · 2024 · External reference
Giredestrant versus physician's choice of endocrine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: primary results from the phase II acelERA BC study
10.1200/jco.23.01500 · 2024 · External reference
AMEERA-3: randomized phase II study of amcenestrant (oral selective estrogen receptor degrader) versus standard endocrine monotherapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
10.1200/jco.22.02746 · 2023 · External reference
Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer (VERITAC-2; NCT05654623)
10.1056/nejmoa2505725 · 2025 · External reference
Giredestrant plus everolimus versus endocrine therapy plus everolimus in ER-positive, HER2-negative advanced breast cancer: results from the phase III evERA BC trial
2025 · External reference
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for ER+/HER2- advanced breast cancer
10.1177/17588359221083956 · 2024 · External reference
First-line camizestrant for emerging ESR1-mutated advanced breast cancer
10.1056/nejmoa2502929 · 2025 · External reference
CDK4/6 inhibitor resistance in HR+HER2- breast cancer: mechanisms and treatment strategies
10.3892/ijmm.2022.5184 · 2024 · External reference
New endocrine therapies for hormone receptor-positive breast cancer
10.1146/annurev-med-052423-122001 · 2025 · External reference
Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update
10.1200/jco.21.01392 · 2021 · External reference
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
10.1016/j.annonc.2021.09.019 · 2021 · External reference
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial
10.1016/j.annonc.2025.11.018 · 2026 · External reference
